Browse the search results

SOX2 causes resistance to anti-EGFR therapies in EGFR-mutant lung cancer.

While HIV-1 Gag protein binds tightly to several RNAs, it binds to the viral RNA 'packaging signal' with higher specificity than to control RNAs.

Targeting Werner syndrome helicase might constitute a novel opportunity for the treatment of a clinically defined subset of patients harboring MSI-H/MMR-deficient tumors.

Lineage transformation in lung cancer is dictated by ERK activity and requires permissive chromatin alterations in the context of targeted therapy resistance.

Maternal embryonic leucine zipper kinase (MELK) is a new anti-cancer target that is highly selective for basal-like breast cancer.

Treatment with precision nanomedicine in combination with an anti-angiogenic peptide enhance anti-tumor efficacy while minimizing toxicities in a pre-clinical glioblastoma model, making this approach a promising and important therapeutic alternative for patients.

Stem-cell-based neural replacement, in combination with optogenetic stimulation, could represent a translationally viable therapeutic strategy to overcome atrophy and paralysis of targeted muscles in people living with amyotrophic lateral sclerosis.

EZH2/cMET may serve as biomarkers to stratify chondrosarcoma patients for cMET inhibitor treatment.

Breast cancer resistant to either doxorubicin or epirubicin relies on distinct primary metabolic processes, which can be targeted to reduce cancer progression.